Literature DB >> 24726882

Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.

Jingwei Lu1, Manjusri Das1, Suman Kanji1, Reeva Aggarwal1, Matthew Joseph1, Alo Ray1, Charles L Shapiro2, Vincent J Pompili1, Hiranmoy Das3.   

Abstract

Many ovarian cancer cells express stress-related molecule MICA/B on their surface that is recognized by Vγ2Vδ2 T cells through their NKG2D receptor, which is transmitted to downstream stress-signaling pathway. However, it is yet to be established how Vγ2Vδ2 T cell-mediated recognition of MICA/B signal is transmitted to downstream stress-related molecules. Identifying targeted molecules would be critical to develop a better therapy for ovarian cancer cells. It is well established that ATM/ATR signal transduction pathways, which is modulated by DNA damage, replication stress, and oxidative stress play central role in stress signaling pathway regulating cell cycle checkpoint and apoptosis. We investigated whether ATM/ATR and its down stream molecules affect Vγ2Vδ2 T cell-mediated cytotoxicity. Herein, we show that ATM/ATR pathway is modulated in ovarian cancer cells in the presence of Vγ2Vδ2 T cells. Furthermore, downregulation of ATM pathway resulted downregulation of MICA, and reduced Vγ2Vδ2 T cell-mediated cytotoxicity. Alternately, stimulating ATM pathway enhanced expression of MICA, and sensitized ovarian cancer cells for cytotoxic lysis by Vγ2Vδ2 T cells. We further show that combining currently approved chemotherapeutic drugs, which induced ATM signal transduction, along with Vγ2Vδ2 T cells enhanced cytotoxicity of resistant ovarian cancer cells. These findings indicate that ATM/ATR pathway plays an important role in tumor recognition, and drugs promoting ATM signaling pathway might be considered as a combination therapy together with Vγ2Vδ2 T cells for effectively treating resistant ovarian cancer cells.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATM/ATR pathway; Combination therapy; Cytotoxicity; MICA; Ovarian cancer; Vγ2Vδ2 T cells

Mesh:

Substances:

Year:  2014        PMID: 24726882      PMCID: PMC4082796          DOI: 10.1016/j.bbadis.2014.04.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  50 in total

1.  Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Authors:  Karuppaiyah Selvendiran; Liyue Tong; Anna Bratasz; M Lakshmi Kuppusamy; Shabnam Ahmed; Yazhini Ravi; Nancy J Trigg; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

2.  PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.

Authors:  Zahra Faghiri; Nicolas G Bazan
Journal:  Exp Eye Res       Date:  2010-03-15       Impact factor: 3.467

3.  Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.

Authors:  Toshiki Tanaka; H Dorota Halicka; Frank Traganos; Karen Seiter; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2007-02-09       Impact factor: 4.534

Review 4.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 5.  Gammadelta T cell modulation in anticancer treatment.

Authors:  Nadia Caccamo; Francesco Dieli; Serena Meraviglia; Giuliana Guggino; Alfredo Salerno
Journal:  Curr Cancer Drug Targets       Date:  2010-02       Impact factor: 3.428

6.  The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.

Authors:  Yan Li; Da-Qing Yang
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

Review 7.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

8.  Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.

Authors:  Jaafar Bennouna; Emmanuelle Bompas; Eve Marie Neidhardt; Frédéric Rolland; Irène Philip; Céline Galéa; Samuel Salot; Soraya Saiagh; Marie Audrain; Marie Rimbert; Sylvie Lafaye-de Micheaux; Jérôme Tiollier; Sylvie Négrier
Journal:  Cancer Immunol Immunother       Date:  2008-02-27       Impact factor: 6.968

9.  ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS.

Authors:  Angela Alexander; Sheng-Li Cai; Jinhee Kim; Adrian Nanez; Mustafa Sahin; Kirsteen H MacLean; Ken Inoki; Kun-Liang Guan; Jianjun Shen; Maria D Person; Donna Kusewitt; Gordon B Mills; Michael B Kastan; Cheryl Lyn Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 10.  Regulation of ligands for the activating receptor NKG2D.

Authors:  Anita R Mistry; Chris A O'Callaghan
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

View more
  4 in total

Review 1.  The T cell antigen receptor: the Swiss army knife of the immune system.

Authors:  M Attaf; M Legut; D K Cole; A K Sewell
Journal:  Clin Exp Immunol       Date:  2015-05-14       Impact factor: 4.330

Review 2.  The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.

Authors:  Mateusz Legut; David K Cole; Andrew K Sewell
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

3.  Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment.

Authors:  Xian Chen; Wenwen Shang; Rui Xu; Ming Wu; Xiaojie Zhang; Peijun Huang; Fang Wang; Shiyang Pan
Journal:  J Transl Med       Date:  2019-05-07       Impact factor: 5.531

Review 4.  Molecular Determinants of Target Cell Recognition by Human γδ T Cells.

Authors:  André E Simões; Biagio Di Lorenzo; Bruno Silva-Santos
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.